glp3.wiki
Investigational · not FDA approved

Editorially reviewed · Last updated September 8, 2026 · How we review

Retatrutide vs CagriSema (Cagrilintide + Semaglutide): Triple Agonist vs Amylin + GLP-1 Combo

Part of Weight Loss Drug Comparison Index.

Retatrutide vs CagriSema (Cagrilintide + Semaglutide): Triple Agonist vs Amylin + GLP-1 Combo

Retatrutide and CagriSema represent two fundamentally different approaches to next-generation obesity treatment. Retatrutide is a single molecule that activates three receptors (GLP-1, GIP, and glucagon). CagriSema is a combination of two separate drugs — cagrilintide (an amylin analog) and semaglutide (a GLP-1 agonist) — delivered together in one injection.

Both are made by different companies (Eli Lilly vs Novo Nordisk), target different biological pathways, and have reported Phase 3 results. CagriSema is further along in the regulatory process, with an NDA filed in December 2025. Retatrutide is still completing Phase 3 trials.

Side-by-Side Comparison

RetatrutideCagriSema
DeveloperEli LillyNovo Nordisk
MechanismTriple agonist: GLP-1 + GIP + GlucagonCombination: Amylin analog (cagrilintide) + GLP-1 agonist (semaglutide)
AdministrationOnce-weekly injection (single peptide)Once-weekly injection (two peptides in one)
Selected weight loss (Phase 3)-28.7% at 68 weeks (TRIUMPH-4, 12 mg)-22.7% at 68 weeks (REDEFINE 1)
Phase 3 programTRIUMPH (first readout Dec 2025)REDEFINE (multiple trials completed)
FDA filingNot yet filedNDA submitted December 2025
Expected approvalBLA planned Q1 2027; approval date unknownDecision expected late 2026; not guaranteed
GI side effectsSimilar to GLP-1 class~80% (mild-moderate, transient)
Safety signal to monitorDysesthesia (8.8-20.9%)GI events common; no direct safety comparison
Discontinuation (AEs)12-18% (Phase 3)~6% (REDEFINE 1)

Cagrilintide vs Retatrutide: How the Mechanisms Differ

Retatrutide: Three Receptors, One Molecule

Retatrutide activates GLP-1, GIP, and glucagon receptors with a single peptide. Glucagon receptor activation is being studied for effects on energy expenditure and hepatic fat metabolism. Preclinical studies support this rationale, but the human trials do not isolate how much weight loss each receptor contributes. Counting receptor targets cannot establish which drug is better.

For details on each receptor, see How Does Retatrutide Work?.

CagriSema: Two Drugs Working Together

CagriSema combines two separate mechanisms:

Cagrilintide (2.4 mg) is a long-acting analog of amylin, a hormone co-secreted with insulin from pancreatic beta cells after meals. Amylin promotes satiety by acting on both homeostatic and hedonic (reward) brain regions via the area postrema. It slows gastric emptying and suppresses post-meal glucagon secretion. Cagrilintide is engineered with prolonged action through reversible albumin binding, enabling once-weekly dosing.
Semaglutide (2.4 mg) is the same GLP-1 agonist in Wegovy/Ozempic — the most well-established obesity drug on the market.

The combination targets appetite through two complementary brain pathways (amylin + GLP-1), producing additive weight loss beyond what either component achieves alone. In REDEFINE 1, CagriSema (-22.7%) significantly outperformed both cagrilintide alone (-11.8%) and semaglutide alone (-16.1%).

The Key Difference

Glucagon receptor activation is being studied for effects on energy expenditure and hepatic fat metabolism. Preclinical studies support this rationale, but the human trials do not isolate how much weight loss each receptor contributes. Counting receptor targets cannot establish which drug is better.

The 28.7% TRIUMPH-4 and 22.7% REDEFINE 1 efficacy-estimand results come from separate trials. They do not show that glucagon activation explains the difference or establish retatrutide superiority.

Cagrilintide vs Retatrutide vs Tirzepatide: Receptor Targets

Swipe sideways to see every column.

ReceptorRetatrutideCagriSemaTirzepatide (Zepbound)
GLP-1YesYes (via semaglutide)Yes
GIPYesNoYes
GlucagonYesNoNo
AmylinNoYes (via cagrilintide)No
Total pathways322
Selected weight loss-28.7%-22.7%-22.5%

Retatrutide and CagriSema each cover pathways the other does not. Retatrutide has GIP and glucagon but no amylin agonism. CagriSema has amylin agonism but no GIP or glucagon. Tirzepatide overlaps with retatrutide on GLP-1 and GIP but lacks both glucagon and amylin.

Weight Loss Comparison

Phase 3 Results

Swipe sideways to see every column.

DrugTrialDurationWeight LossParticipants
Retatrutide 12 mgTRIUMPH-468 weeks-28.7%445
Retatrutide 9 mgTRIUMPH-468 weeks-26.4%445
CagriSemaREDEFINE 168 weeks-22.7%3,417
Semaglutide 2.4 mg aloneREDEFINE 168 weeks-16.1%3,417
Cagrilintide 2.4 mg aloneREDEFINE 168 weeks-11.8%3,417

Weight Loss Thresholds (CagriSema, REDEFINE 1)

Novo Nordisk reported that more than 40% of CagriSema participants achieved at least 25% weight loss under the REDEFINE 1 efficacy estimand. Threshold percentages vary with the estimand; they should not be mixed with treatment-policy figures or compared as if randomized against retatrutide. Source.

CagriSema in Type 2 Diabetes (REDEFINE 2)

In adults with type 2 diabetes, CagriSema produced -15.7% weight loss at 68 weeks vs -3.1% for placebo. Weight loss is consistently lower in diabetic populations across all GLP-1 class drugs. Retatrutide now has Phase 3 diabetes results: TRANSCEND-T2D-1 reported HbA1c and weight outcomes in March 2026. These are separate populations and studies.

Important Caveat

These results come from different trials with different patient populations. TRIUMPH-4 enrolled patients with obesity and knee osteoarthritis (445 participants). REDEFINE 1 enrolled a broader obesity population (3,417 participants). The only definitive comparison would be a randomized head-to-head trial, which does not exist.

Side Effects and Tolerability

Retatrutide (TRIUMPH-4)CagriSema (REDEFINE 1)
Most commonNausea, diarrhea, constipation, vomitingNausea, vomiting, diarrhea, constipation, abdominal pain
GI event rateConsistent with GLP-1 class~80% (vs ~40% placebo)
SeverityMostly mild-moderateMostly mild-moderate, transient
Discontinuation (AEs)12-18%~6% (vs 3.7% placebo)
Reported signalDysesthesia (tingling/burning) in 8.8-20.9%GI events common; no direct safety comparison
The discontinuation percentages are from different studies, so they cannot establish which drug is easier to tolerate. Dysesthesia (altered skin sensation) occurred in 8.8% and 20.9% of the retatrutide 9 mg and 12 mg groups in TRIUMPH-4. It is not unique to retatrutide: current Wegovy and Zepbound labels also report it. A glucagon-specific cause has not been established.

Regulatory Timeline

MilestoneCagriSemaRetatrutide
Phase 3 programREDEFINE (multiple trials completed)TRIUMPH (first readout Dec 2025)
NDA filedDecember 18, 2025Not yet filed
FDA reviewUnder review, decision expected 2026—
Expected approvalDecision expected late 2026BLA planned Q1 2027; approval date unknown
Head-to-head trialREDEFINE 4 reported February 2026; noninferiority not metNone against CagriSema
CagriSema has been submitted for FDA review. Lilly plans a US biologics license application in the first quarter of 2027. That is a filing target, not an FDA approval or launch date.
A relevant completed head-to-head trial is REDEFINE 4: at 84 weeks, CagriSema produced 23.0% weight loss versus 25.5% with tirzepatide under the efficacy estimand. Treatment-regimen estimates were 20.2% and 23.6%. CagriSema did not meet the primary noninferiority endpoint. These results do not directly compare either treatment with retatrutide.

Can You Combine Cagrilintide With Retatrutide?

People searching for "cagrilintide with retatrutide" or "cagrilintide and retatrutide together" are asking about stacking these two peptides. Here is what the evidence says.

The Scientific Rationale

There is a plausible theoretical basis for combining them. Cagrilintide activates amylin receptors — a pathway that retatrutide does not touch. Together, they would cover four distinct receptor systems (GLP-1, GIP, glucagon, and amylin), potentially producing greater appetite suppression and weight loss than either drug alone.

REDEFINE 1 supports combining cagrilintide with semaglutide in that studied formulation. It does not validate substituting retatrutide or assembling a combination from separately sourced peptides.

Eli Lilly appears to recognize this logic. The company is studying eloralintide, its own amylin receptor agonist, in combination with tirzepatide in a Phase 2 trial — suggesting that amylin + incretin combinations are an active area of pharmaceutical development.

What the Data Actually Shows

No published clinical evidence retrieved for this review establishes the safety or efficacy of cagrilintide plus retatrutide. Evidence for CagriSema cannot be transferred to that combination.

Safety Concerns

Without clinical data, safety risks can only be inferred:

  • Additive GI side effects — both drugs slow gastric emptying through different mechanisms. Combining them could increase nausea, vomiting, and gastroparesis risk beyond what either drug causes alone.
  • Excessive appetite suppression — amylin agonism is a potent appetite suppressant. Combined with retatrutide's triple mechanism, caloric intake could drop to levels that promote muscle loss and nutritional deficiencies.
  • No long-term safety data — neither drug has multi-year safety data on its own, let alone in combination.

The Bottom Line

The scientific rationale for combining amylin agonism with incretin-based therapy is real and supported by CagriSema's clinical results. However, no data exists for the specific cagrilintide + retatrutide combination. Anyone considering this combination should discuss it with their physician.

Frequently Asked Questions

Which produces more weight loss — retatrutide or CagriSema?

Selected separate trials reported 28.7% with retatrutide in TRIUMPH-4 and 22.7% with CagriSema in REDEFINE 1 at 68 weeks under efficacy estimands. Neither result establishes a difference between the drugs because participants were not randomized between them. REDEFINE 4 compared CagriSema with tirzepatide, not retatrutide.

Is CagriSema just Wegovy plus another drug?

Essentially, yes. CagriSema combines semaglutide (the active ingredient in Wegovy) with cagrilintide, a long-acting amylin analog. The combination produces about 6-7 percentage points more weight loss than semaglutide alone.

What is amylin and why does it help with weight loss?

Amylin is a hormone co-secreted with insulin from pancreatic beta cells after meals. It promotes satiety by acting on brain regions involved in both hunger signaling (homeostatic) and food reward/craving (hedonic). It also slows gastric emptying and suppresses post-meal glucagon. Cagrilintide is an engineered long-acting version of amylin.

Will CagriSema be available before retatrutide?

CagriSema is further along in regulatory review, with a decision expected in late 2026. Lilly plans a US biologics license application in the first quarter of 2027. That is a filing target, not an FDA approval or launch date. Neither projected milestone guarantees availability.

Can you take CagriSema while waiting for retatrutide?

This would be a decision for your doctor. CagriSema, if approved, would be an option for patients who cannot wait for retatrutide. Switching protocols between the two drugs have not been studied.

Can you stack cagrilintide with retatrutide?

There is a plausible scientific rationale — cagrilintide targets amylin receptors, which retatrutide does not — but no clinical trial has studied this combination. The two drugs are made by competing companies (Novo Nordisk vs Eli Lilly). Safety data for combining them does not exist, and additive GI side effects are a concern. Discuss any combination therapy with your physician.

How does cagrilintide compare to retatrutide for weight loss?

Cagrilintide alone produced 11.8% weight loss at 68 weeks under the REDEFINE 1 efficacy estimand; retatrutide 12 mg produced 28.7% in a separate TRIUMPH-4 population. Cagrilintide is being developed both alone and with semaglutide. These are different treatment questions, and no direct cagrilintide–retatrutide comparison establishes which is better.

Is cagrilintide a GLP-1 drug?

No. Cagrilintide is an amylin analog, not a GLP-1 agonist. Amylin is a separate hormone co-secreted with insulin from pancreatic beta cells. Cagrilintide works through amylin and calcitonin receptors, which are distinct from the GLP-1, GIP, and glucagon receptors that retatrutide targets.

Sources

How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov

Keep exploring

Explore all compare topics →